FDA Warning to Sprout Health Signals Tighter Scrutiny of GLP-1 Compounders

Sprout Health Partners LLC is the latest compounding operation to draw FDA enforcement action over misleading claims about compounded GLP-1 receptor agonists, a pattern that should put QA and regulatory affairs teams across the compounding sector on high alert. The agency issued a warning letter on September 9, 2025, citing the company's website for claiming that "GLP-1 medications are FDA-approved and backed by extensive clinical research" in connection with compounded semaglutide and tirzepatide products. The FDA's Center for Drug Evaluation and Research (CDER), through its Office of Compounding Quality and Compliance (OCQC), determined that this language misbrands the products under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FDCA), because compounded drug products are not FDA-approved and the claim implies equivalence with approved products.

The enforcement action fits squarely within the FDA's escalating campaign against compounders whose labeling or promotional materials blur the line between compounded preparations and their FDA-approved reference listed drugs. For plant heads and QA directors at 503A and 503B facilities producing compounded semaglutide or tirzepatide, the letter is a concrete reminder that even seemingly general marketing language on a website can trigger misbranding charges under 21 U.S.C. §§ 352(a) and 352(bb). The introduction of such misbranded products into interstate commerce constitutes a prohibited act under section 301(a) of the FDCA [21 U.S.C. § 331(a)], and the FDA explicitly warned that failure to address the violations could result in seizure and injunction without further notice.

The specific violation identified in the Sprout Health letter is narrow but instructive. The company's website, reviewed by FDA in August 2025 at https://joinsprouthealth.com, offered compounded semaglutide and tirzepatide products alongside the claim referencing FDA approval. The FDA noted that this claim "implies that your products are the same as an FDA-approved product when they are not." Critically, the agency also stated that the cited violation "does not represent an exhaustive list of misbranding violations," signaling that additional compliance gaps may exist. Sprout Health was given 15 working days from receipt of the letter to provide a written response to OCQC describing corrective actions taken and documentation of steps to prevent recurrence.

For regulatory affairs leads and compliance officers at compounding operations, the operational takeaway is clear: every piece of customer-facing content, from website copy to patient-facing materials, must unambiguously distinguish compounded products from FDA-approved drugs. Under 21 CFR Part 211 and applicable compounding regulations, the responsibility for accurate labeling and promotion rests with the facility. QA teams should conduct immediate audits of all promotional and labeling materials to identify language that could be construed as implying FDA approval or therapeutic equivalence. Any reference to clinical research supporting the active pharmaceutical ingredient should be carefully framed to avoid suggesting that the compounded formulation itself has undergone FDA review or approval.

The broader enforcement landscape around compounded GLP-1 products continues to tighten. As the FDA works to protect patients from confusion between compounded and commercially approved semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), compounding facilities should expect continued scrutiny of both product quality and promotional practices. Facilities that have not yet reviewed their labeling and advertising against sections 502(a) and 502(bb) of the FDCA should treat this warning letter as a prompt to do so before they become the next target of CDER enforcement. The full warning letter is available on the FDA's warning letters page.